Patents Assigned to Xiamen University
-
Patent number: 9162222Abstract: The present disclosure relates to a surface structure control and preparation process for a metal nanocatalyst involving a metal nanocatalyst. The present disclosure provides a surface structure control and continuous preparation system for a metal nanocatalyst, a metal nanocatalyst having an open surface structure and high surface energy, and a surface structure control and a preparation process thereof. The system is provided with a nucleation electrolytic cell, a distribution valve, at least two growth electrolytic cells, with two ends of the distribution valve being connected to an output port of the nucleation electrolytic cell and to input port of all the growth electrolytic cells, respectively. The metal nanocatalyst having an open surface structure is a single metal nanoscale crystal and has a high density of terrace atoms or active sites on the surface thereof.Type: GrantFiled: June 13, 2011Date of Patent: October 20, 2015Assignee: XIAMEN UNIVERSITYInventors: Shi-gang Sun, Rui Huang, Sheng-pei Chen
-
Publication number: 20150246948Abstract: The present invention relates to epitope peptides (or mutants thereof) for treating hepatitis B virus infection, recombinant proteins comprising such epitope peptides (or mutants thereof) and carrier proteins, and uses of such epitope peptides (or mutants thereof) and recombinant proteins. The present invention also relates to antibodies against such epitope peptides, cell lines producing said antibodies, and uses thereof. Furthermore, the present invention relates to vaccines or pharmaceutical compositions for treating or alleviating one or more symptoms associated with hepatitis B virus infection, which comprise the recombinant proteins or antibodies according to the invention, respectively.Type: ApplicationFiled: June 6, 2013Publication date: September 3, 2015Applicants: XIAMEN UNIVERSITY, XIAMEN INNOVAX BIOTECH CO., LTD.Inventors: Quan Yuan, Tianying Zhang, Wenxin Luo, Yixin Chen, Jun Zhang, Ningshao Xia
-
Publication number: 20140288283Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 6, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.Type: ApplicationFiled: April 8, 2014Publication date: September 25, 2014Applicants: BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD., XIAMEN UNIVERSITYInventors: Shaowei Li, Huirong Pan, Bo Liu, Jun Zhang, Ji Miao, Ningshao Xia
-
Publication number: 20140162898Abstract: The present invention relates to a method and a kit for detecting nucleic acid sequence variation using melting curve analysis, especially relates to a method and a kit for detecting nucleic acid sequence variation by melting curve analysis using self-quenched probe. Said method provides the characteristics of the self-quenched probe employed, as well as the corresponding nucleic acid amplification conditions, so that the probe can bind to the amplified target sequence, and variations of the target sequence can be detected by melting curve analysis. The present invention also encompasses a kit assembled according to the method described.Type: ApplicationFiled: February 17, 2014Publication date: June 12, 2014Applicant: XIAMEN UNIVERSITYInventors: Qingge LI, Qiuying HUANG
-
Patent number: 8748127Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 6, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.Type: GrantFiled: May 29, 2008Date of Patent: June 10, 2014Assignees: Xiamen University, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.Inventors: Shaowei Li, Huirong Pan, Bo Liu, Jun Zhang, Ji Miao, Ningshao Xia
-
Publication number: 20140147460Abstract: The present invention relates to a truncated L1 protein of Human Papillomavirus (HPV) Type 33, a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein and the virus-like particle are useful for preventing HPV (particularly HPV33) infection, and a disease caused by HPV (particularly HPV33) infection, such as cervical cancer. The invention also relates to the use of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine for preventing HPV (particularly HPV33) infection, and a disease caused by HPV (particularly HPV33) infection, such as cervical cancer.Type: ApplicationFiled: May 22, 2012Publication date: May 29, 2014Applicants: XIAMEN INNOVAX BIOTECH CO. LTD., XIAMEN UNIVERSITYInventors: Shaowei Li, Xianglin Kong, Minxi Wei, Huirong Pan, Jun Zhang, Ningshao Xia
-
Publication number: 20140134199Abstract: Provided in the present invention are a diphtheria toxin non-toxic mutant CRM197 or a fragment thereof as an adjuvant in a fusion protein and the use thereof to enhance the immunogenicity of a target protein fused therewith, for example, an HEV capsid protein, or an influenza virus M2 protein or an immunogenic fragment thereof. Also provided is a method for enhancing the immunogenicity of a target protein, comprising the fusion expression of the CRM197 or the fragment thereof with the target protein to form a fusion protein. Further provided is a fusion protein comprising the CRM197 or the fragment thereof and a target protein, the CRM197 or the fragment thereof enhancing the immunogenicity of the target protein. The present invention also provides an isolated nucleic acid encoding the fusion protein, a construct and a vector comprising said nucleic acid, and a host cell comprising the nucleic acid.Type: ApplicationFiled: June 1, 2012Publication date: May 15, 2014Applicants: XIAMEN INNOVAX BIOTECH CO., LTD., XIAMEN UNIVERSITYInventors: Shaowei Li, Cuiling Song, Chunyan Yang, Ying Gu, Wenxin Luo, Ningshao Xia
-
Patent number: 8715695Abstract: The present invention relates to polypeptide(s) comprising the amino acid sequence as set forth in SEQ ID No. 1 of hepatitis E virus ORF 2 or its fragment, which is in the form of n-polymeric polypeptide, wherein n is an integer from 1-180; to a chimeric protein consisting of a polypeptide of the present invention and a conserved fragment of hemagglutin antigen from influenza virus; to a polypeptide of the present invention bound to a polypeptide containing epitope from hepatitis E virus ORF3 or an immunogenic fragment thereof; to a recombinant expression vector comprising the DNA molecule encoding the above polypeptides and the host cell transformed with said recombinant expression vector which is able to express polypeptide of the present invention.Type: GrantFiled: September 11, 2009Date of Patent: May 6, 2014Assignees: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Xiamen UniversityInventors: Ningshao Xia, Jun Zhang, Shaowei Li, Shengxiang Ge, Ying Gu, Zhiqiang He
-
Patent number: 8691504Abstract: The present invention relates to a method and a kit for detecting nucleic acid sequence variation using melting curve analysis, especially relates to a method and a kit for detecting nucleic acid sequence variation by melting curve analysis using self-quenched probe. Said method provides the characteristics of the self-quenched probe employed, as well as the corresponding nucleic acid amplification conditions, so that the probe can bind to the amplified target sequence, and variations of the target sequence can be detected by melting curve analysis. The present invention also encompasses a kit assembled according to the method described.Type: GrantFiled: May 26, 2010Date of Patent: April 8, 2014Assignee: Xiamen UniversityInventors: Qingge Li, Qiuying Huang
-
Patent number: 8603467Abstract: The present invention provides monoclonal antibodies that bind specifically to H5 subtype avian influenza virus hemagglutinin (HA) proteins, and can block the binding activity of at least 50% of the known monoclonal antibodies to the H5 subtype avian influenza virus hemagglutinin (HA) protein. The monoclonal antibodies can be used for the detection, diagnosis, prevention, and treatment of avian influenza viruses, especially the H5 subtype of avian influenza viruses. The present invention also provides the related hybridoma cell lines, isolated nucleic acid molecules and short peptides, as well as medical composition and medical diagnostic equipment and kit containing the monoclonal antibody.Type: GrantFiled: June 16, 2008Date of Patent: December 10, 2013Assignees: Xiamen University, Yang Sheng Tang CompanyInventors: Yixin Chen, Wenxin Luo, Jun Zhang, Ningshao Xia, Yi Guan, Honglin Chen
-
Publication number: 20130295124Abstract: Provided are an ORF7 deficient varicella virus, an vaccine comprising the virus and use thereof, as well as a method for the production the virus.Type: ApplicationFiled: July 27, 2010Publication date: November 7, 2013Applicants: New Jersey Medical School, Xiamen University, Beijing Wantai Biological Pharmacy Enterprise Co.,Inventors: Hua Zhu, Yimin Li, Ningshao Xia, Tong Cheng, Xiangzhong Ye
-
Publication number: 20130230548Abstract: Provided is a truncated L1 protein of Human Papillomavirus (HPV) Type 52 which, compared to a wild type HPV52 L1 protein, is truncated by 27-42 amino acids at the N-terminal. Also provided are a coding sequence of the truncated HPV52 L1 protein, a virus-like particle (VLP) comprising the protein, and a method of preparing the protein and the VLP using an E. coli expression system. The truncated HPV52 L1 protein and an assembled VLP can be used to prevent an HPV52 infection and a disease caused by HPV52 infection, such as cervical cancer.Type: ApplicationFiled: July 1, 2011Publication date: September 5, 2013Applicant: XIAMEN UNIVERSITYInventors: Shaowei Li, Xiaobing Mo, Minxi Wei, Huirong Pan, Jun Zhang, Ningshao Xia
-
Patent number: 8524868Abstract: The present invention relates to polypeptide(s) comprising the amino acid sequence as set forth in SEQ ID No. 1 of hepatitis E virus ORF 2 or its fragment, which is in the form of n-polymeric polypeptide, wherein n is an integer from 1-180; to a chimeric protein consisting of a polypeptide of the present invention and a conserved fragment of hemagglutin antigen from influenza virus; to a polypeptide of the present invention bound to a polypeptide containing epitope from hepatitis E virus ORF3 or an immunogenic fragment thereof; to a recombinant expression vector comprising the DNA molecule encoding the above polypeptides and the host cell transformed with said recombinant expression vector which is able to express polypeptide of the present invention.Type: GrantFiled: November 9, 2009Date of Patent: September 3, 2013Assignees: Beijing Wantai Biological Pharmacy Enterprise Co., Ltd., Xiamen UniversityInventors: Ningshao Xia, Jun Zhang, Shaowei Li, Shengxiang Ge, Ying Gu, Zhiqiang He
-
Publication number: 20130184146Abstract: The present disclosure relates to a surface structure control and preparation process for a metal nanocatalyst involving a metal nanocatalyst. The present disclosure provides a surface structure control and continuous preparation system for a metal nanocatalyst, a metal nanocatalyst having an open surface structure and high surface energy, and a surface structure control and a preparation process thereof. The system is provided with a nucleation electrolytic cell, a distribution valve, at least two growth electrolytic cells, with two ends of the distribution valve being connected to an output port of the nucleation electrolytic cell and to input port of all the growth electrolytic cells, respectively. The metal nanocatalyst having an open surface structure is a single metal nanoscale crystal and has a high density of terrace atoms or active sites on the surface thereof.Type: ApplicationFiled: June 13, 2011Publication date: July 18, 2013Applicant: XIAMEN UNIVERSITYInventors: Shi-gang Sun, Rui Huang, Sheng-pei Chen
-
Publication number: 20120301449Abstract: The RNAi target sequences, which could be used for treating AIDS through targeting HIV. Based on the target sequences, recombinant expression vectors, packaging vectors and cells were constructed, which express siRNA and/or miRNA and/or ribozyme and/or antisense oligonucleotide for targeting HIV. And the applications of said recombinant expression vectors, packaging vectors and cells in preparing medicament for treating AIDS.Type: ApplicationFiled: August 13, 2012Publication date: November 29, 2012Applicants: YANG SHENG TANG COMPANY LIMITED, XIAMEN UNIVERSITYInventors: TONG CHENG, TAO ZHANG, YALI ZHANG, JI MIAO, JUN ZHANG, NINGSHAO XIA
-
Publication number: 20120289429Abstract: A biochip includes a plurality of microchannels; and a plurality of probes disposed in an inner wall of each of the plurality of microchannels forming a one-dimensional array. The one-dimensional array of probes are configured to react with a sample in the microchannel. The plurality of microchannels are arranged such that the plurality of probes of the plurality of microchannels form a two-dimensional or three-dimensional array.Type: ApplicationFiled: July 20, 2012Publication date: November 15, 2012Applicant: XIAMEN UNIVERSITYInventors: Hong CHEN, Xiangmeng Qu
-
Publication number: 20120141995Abstract: The present invention discloses a method for detecting multiple single nucleotide variations or polymorphisms in a single reaction tube, and the oligonucleotide, the probe, the set of probes, the kit used, as well as the use thereof. Specifically, it relates to a method for identifying the genotype of multiple single nucleotide variation or SNP sites from the melting temperature of a kind of artificial melting temperature tag sequence (AMTS) and the type of fluorescence labels.Type: ApplicationFiled: May 26, 2010Publication date: June 7, 2012Applicant: XIAMEN UNIVERSITYInventors: Qingge Li, Qiuying Huang, Xiaobo Wang
-
Publication number: 20120077195Abstract: The present invention relates to a method and a kit for detecting nucleic acid sequence variation using melting curve analysis, especially relates to a method and a kit for detecting nucleic acid sequence variation by melting curve analysis using self-quenched probe. Said method provides the characteristics of the self-quenched probe employed, as well as the corresponding nucleic acid amplification conditions, so that the probe can bind to the amplified target sequence, and variations of the target sequence can be detected by melting curve analysis. The present invention also encompasses a kit assembled according to the method described.Type: ApplicationFiled: May 26, 2010Publication date: March 29, 2012Applicant: XIAMEN UNIVERSITYInventors: Qingge Li, Qiuying Huang
-
Patent number: 8094433Abstract: A supercapacitor having a main energy storage form that is based on the electrode reaction of electrochemical active materials in a thin liquid layer near the inner and outer surfaces of porous electrodes.Type: GrantFiled: April 10, 2007Date of Patent: January 10, 2012Assignee: Xiamen UniversityInventors: Zhao-Wu Tian, Quan-Feng Dong, Ming-Sen Zheng, Zu-Geng Lin
-
Publication number: 20110311522Abstract: The present invention provides monoclonal antibodies that bind specifically to H5 subtype avian influenza virus hemagglutinin (HA) proteins, and can block the binding activity of at least 50% of the known monoclonal antibodies to the H5 subtype avian influenza virus hemagglutinin (HA) protein. The monoclonal antibodies can be used for the detection, diagnosis, prevention, and treatment of avian influenza viruses, especially the H5 subtype of avian influenza viruses. The present invention also provides the related hybridoma cell lines, isolated nucleic acid molecules and short peptides, as well as medical composition and medical diagnostic equipment and kit containing the monoclonal antibody.Type: ApplicationFiled: June 16, 2008Publication date: December 22, 2011Applicant: XIAMEN UNIVERSITYInventors: Yixin Chen, Wenxin Luo, Jun Zhang, Ningshao Xia, Yi Guan, Honglin Chen